Navigation Links
Palatin Technologies Announces Issuance of Two Natriuretic Peptide Receptor-Specific Mimetic Patents
Date:11/12/2013

CRANBURY, N.J., Nov. 12, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that the United States Patent and Trademark Office today issued two new patents to Palatin.  Both patents support Palatin's program developing synthetic mimetics of the neuropeptide hormone atrial natriuretic peptide. These mimetics may be useful in treatment of acute asthma, other pulmonary diseases, heart failure, hypertension and other indications.

U.S. Patent 8,580,747, entitled "Cyclic Natriuretic Peptide Constructs," has composition of matter claims relating to Palatin's PL-3994 natriuretic peptide receptor-A agonist for treatment of cardiovascular and pulmonary indications.  PL-3994 has completed two early stage human clinical studies, a Phase 1 trial in healthy volunteers and a Phase 2A trial in volunteers with controlled hypertension.

U.S. Patent 8,580,746, entitled "Amide Linkage Cyclic Natriuretic Peptide Constructs," has composition of matter claims to a novel series of mimetics of atrial natriuretic peptide.  These compounds have potential utility in a number of cardiovascular and pulmonary indications.

"We are pleased to have two new issued patents supporting our natriuretic peptide portfolio.  Our mimetic peptides have a much longer half-life than endogenous atrial natriuretic peptide, giving them important drug-like properties," stated Carl Spana, Ph.D., President and CEO of Palatin.

The issued patents have a twenty-year term that will not expire until March 2027.

About Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with sign
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
3. Palatin Technologies, Inc. To Report Fiscal Year 2013 Fourth Quarter Results
4. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2013 Results
5. Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial
6. Palatin Technologies, Inc. To Report First Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on November 14, 2013
7. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
8. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
9. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
10. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
11. Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014  Cyberonics, Inc. (NASDAQ: ... ANTHEM-HF clinical study.  Results of the study presented ... major European cardiology congress and concurrently published by ... Autonomic Regulation Therapy (ART) in patients with moderate ... function is safe, improves the heart,s ability to ...
(Date:9/2/2014)... Sept. 2, 2014  Boston Scientific Corporation (NYSE: ... agreement to purchase the Interventional business of Bayer ... Scientific to offer physicians and healthcare systems a ... vascular conditions. The addition of the ... supports the Boston Scientific strategy to provide a ...
(Date:9/2/2014)... 2, 2014  Based on its recent analysis ... Frost & Sullivan recognizes Novian Health, Inc. with ... for Technology Innovation Leadership. Novian Health has greatly ... tumors with its proprietary technology, Novilase ® ... accurate, and easy-to-control ultrasound-guided thermo ablation device that ...
Breaking Medicine Technology:ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 2ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 3ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 4ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 5Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 2Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 3Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 4Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 5
... NEW YORK, Jan. 13, 2011 Although 2010 brought ... healthcare reform repeal.  Investors should likely expect some volatility ... wreak havoc on healthcare reform, either through a repeal ... according to analysts at Standard & Poor,s Equity Research. ...
... N.J., Jan. 13, 2011 Quest Diagnostics Incorporated (NYSE: ... information and services, announced today that it will report fourth ... for 2011 on Tuesday, January 25, before the market opens. ... discuss the results beginning at 8:30 a.m. ET on that ...
Cached Medicine Technology:S&P Equity Research Issues Health Care Sector Predictions for 2011 2S&P Equity Research Issues Health Care Sector Predictions for 2011 3S&P Equity Research Issues Health Care Sector Predictions for 2011 4S&P Equity Research Issues Health Care Sector Predictions for 2011 5S&P Equity Research Issues Health Care Sector Predictions for 2011 6Quest Diagnostics to Release Fourth Quarter and Full Year 2010 Financial Results 2
(Date:9/2/2014)... 02, 2014 According to a ... the leading global authority in medical device market ... is expected to grow to over €2 billion ... increase in the number of procedures for the ... This market includes TURP devices, laser BPH devices, ...
(Date:9/2/2014)... N.J. (PRWEB) September 02, 2014 ... technologies and development solutions for drugs, biologics and ... of its strategic partner, Eli Lilly’s growth, it ... packaging lines at its Philadelphia Clinical Supply Center ... syringe packaging capabilities in its clinical supply facility ...
(Date:9/2/2014)... York (PRWEB) September 02, 2014 ... of nanotechnology in diagnosing, treating and/or prevention of ... applied for treating cardiovascular, neurological, and oncology diseases. ... of knowledge pertaining to various nanoparticles, their medical ... There still exists considerable scope for research in ...
(Date:9/2/2014)... JOSE, CA (PRWEB) September 02, 2014 ... computing and collaboration, announces partnership with NTT DoCoMo ... iPad business customers. Splashtop Business Lite is included ... Lite is a remote desktop software that empower users ... anywhere. Splashtop has garnered over 18 million users ...
(Date:9/2/2014)... On Saturday, September 6, 2014, The Concilio will ... tu vida! Get Up! Get Moving!®. This event promotes Hispanic ... wellness for people of all ages and all sizes. The ... be held at Kiest Park Recreation Center, 3080 S. Hampton ... , “Since 2007, we have partnered with National Alliance for ...
Breaking Medicine News(10 mins):Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:Catalent Supports Eli Lilly's Growing Global Clinical Trials Needs with New Investment in Automated Packaging Solutions 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:Splashtop and NTT DoCoMo Partner to Deliver “Splashtop Business Lite” Secure Remote Access Solution to Business Customers 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4
... are becoming common everywhere. Only last fortnight it was reported ... 15 ft during a joyride and sustained grievous injuries in ... ,But for a tree branch which checked her ... first aid facilities available, it was reported. ,Now ...
... with Delmont Laboratory to introduce its immunotherapeutic vaccine Staphage ... to this initial agreement, Delmont Laboratory will supply bulk ... the final packaging in China. ,CBPC will ... to be signed. This product requires a clinical study ...
... fill their prescriptions while traveling abroad need to be cautious ... the AAPS National Biotechnology Conference. ,Unlike approved ... internationally. Therefore, consumers should not assume that a branded product ... the same or similar brand name in other counties. ...
... seven billion dollar (5.2 billion euro) negligence suit against ... as the US giant demanded the charges be ... early setback when the court rejected a request to ... Babs Kwewumi adjourned the trial to July 20. ...
... announces that it has completed its acquisition of ... for approximately $600 million on April 4, 2007. ... owns the patents for Electrochemiluminescence (ECL) technology and ... diagnostics field into new market segments such as ...
... called the world's first prototype of an artificial hand with ... up a raw egg. ,Squse, a Kyoto-based ... 400-gramme (14 ounce) hand with five human-sized fingers with artificial ... ,"So far, robots have an image of helping people do ...
Cached Medicine News:Health News:Girls Feet Severed in Amusement Park Accident 2Health News:Nigeria Launches Seven Billion Dollar Case Against Pfizer 2Health News:Nigeria Launches Seven Billion Dollar Case Against Pfizer 3
... SINON is a Q-switched ... wavelength of 694 nm. High ... Pulses - This combination of ... pulses in Q-switched mode effectively ...
... an in vitro immunoassay intended for the qualititive ... antigen. It is indicated for use as an ... conjunction with cystoscopy or when prescribed for in ... FDA for prescription home use in February 1999. ...
... connect an infusion bag ... and then to a ... to conduct urodynamics studies. ... Medical Technologies infusion pumps. ...
... Used for cystometry and urethral ... allows for faster filling of the ... readings. Dual lumen catheter construction allows ... cystometry is performed. Triple lumen catheter ...
Medicine Products: